Close Menu

Regulus

Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding RNAs
Patent Number: 8,133,876
Filed: Dec. 30, 2008
Lead Inventor: Frank Bennett, Regulus Therapeutics

Title: Method and Medicament for Inhibiting the Expression of a Given Gene
Patent Number: 8,114,851
Filed: Oct. 31, 2007
Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals

Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding RNAs
Patent Number: 8,110,558
Filed: Dec. 31, 2008
Lead Inventor: Frank Bennett, Regulus Therapeutics

Regulus Therapeutics said this week that that Australian Patent Office has recently granted certain claims in a company-controlled patent family covering the use of microRNA-122 in treating hepatitis C.

The discovery triggered a milestone payment of an undisclosed amount, Regulus said.

Gregory Hannon

Mice treated with a miR-33 antagonist displayed increased HDL-C, enhanced reverse cholesterol transport to the plasma, liver, and feces, and reductions in plaque size and lipid content.

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.